JAPIA Members Participate in DIA 2025 Global Annual Meeting and Communicate to the World about Efforts to Address Drug Lag and Loss Issues
Explanation at the beginning of this article
2025 On June18, 2006, the Pharmaceutical Manufacturers Association of Japan (PMAJ), the National Cancer Institute (NCI), and the Pharmaceutical Marketing Development Agency of Japan (PMDA) jointly held a session at the DIA 2025 Global Annual Meeting ( DIA-2025 ) held in Washington, D.C., USA. The meeting attracted dozens of audience members, who asked questions from the audience, making it an enthusiastic event.
What is DIA?
The DIA( DIA) is a global non-profit organization that supports innovation in medical product research, development, and lifecycle management by providing educational activities and a forum for information exchange and discussion among regulators, companies, academia, and patients. DIA-2025 was attended by 4,000 participants from 57 countries and regions around the world, who engaged in lively discussions on clinical trials and regulatory issues.
Background of the Meeting
One of the causes of drug-lag loss (especially loss) is the increasing number of drugs created and approved by Emerging BioPharma (EBP) in the U.S. and Europe. Therefore, in order to eliminate drug-lag losses, it was necessary to convey the attractiveness of the Japanese market to EBPs in the U.S. and Europe, and to attract their willingness to invest in Japan.
The Pharmaceutical Manufacturers Association of Japan (PMAJ) has formed a cross-committee task force and has been working with the government and academia to promote clinical trials and improve the pharmaceutical affairs and drug pricing systems. We have been working with academic societies and patient groups in Japan, and now we are pleased to announce that our efforts have been extended outside of Japan.
Session Themes】 【Background】 【Session Themes】 【Session Themes】 【Session Themes
Why Does Drug Loss Occur?
Challenges to be Addressed for Patients, and Japan's Contribution to Globalized Drug Development
Chair: Mr. Toshiharu Sano (Drug Evaluation Committee)
2023 He shared that 86 products were launched in Europe and the U.S. in March, 2006, but not yet developed in Japan, many of which were EBP products, and that in Japan, industry, academia, and government are working together to eliminate drug loss.
Presenter: Kobayashi (Industrial Policy Committee)
He reported that the Japanese government is working on drug loss by positioning the pharmaceutical industry as a "key industry" and that industry-academia-government collaboration is improving the environment of the Japanese market based on the opinions of EBPs who have entered the Japanese market.
Explanation 2 Unlocking Japan's Clinical Trial Landscape - Investigator's Perspective
Presenter: Dr. Kenichi Nakamura (National Cancer Center Hospital)
Dr. Nakamura first sought a correct understanding of the Japanese pharmaceutical market, and then presented the organization of the National Cancer Center and its track record in clinical trials. He also explained about the clinical trial information collaboration efforts in Asia and the opening of a one-stop consultation service for clinical trials at the Center.
Panel Discussion
Chairperson / 2 explainers / Panelist: Akihiro Ishiguro, Director, PMDA Washington D.C. Office
Closing Remarks by Chair
Chair Sano will discuss "The Attractiveness of the Japanese Market and Changes in the Clinical Environment The key points are "changes in the attractiveness of the Japanese market and the clinical environment," "revitalization through the establishment of a one-stop consultation service for global clinical trials," and "utilization of the consultation function at thePMDA Washington D.C. office.
Closing Remarks by Chair】 【Closing Remarks
DIA-2025 was the first time that the Pharmaceutical Manufacturers Association of Japan (PMAJ) planned and presented its own global efforts to combat drug lag and loss. Several committees worked together to make the meeting a success. We would like to thank the speakers and all those who cooperated with us.
Since drug lag and loss is a problem that could occur in the future and is detrimental to patients in Japan, the task force will continue to disseminate the information to the outside world.
Report: Nobuyuki Kobayashi, Task Force on Drug Lag and Loss, Industrial Policy Committee